CN1136894C - Medicinal composition for treating tuberculosis and its preparing process - Google Patents
Medicinal composition for treating tuberculosis and its preparing process Download PDFInfo
- Publication number
- CN1136894C CN1136894C CNB011156023A CN01115602A CN1136894C CN 1136894 C CN1136894 C CN 1136894C CN B011156023 A CNB011156023 A CN B011156023A CN 01115602 A CN01115602 A CN 01115602A CN 1136894 C CN1136894 C CN 1136894C
- Authority
- CN
- China
- Prior art keywords
- gram
- pharmaceutical composition
- gallus domesticus
- ovum gallus
- domesticus album
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a medicinal composition for treating tuberculosis, particularly to for treating pulmonary tuberculosis. The present invention contains musk, stemona roots, green chiretta, aster, mustard, schisandra fruits, scutellaria roots, ginseng rootlets, bupleurum roots, flavescent sophora roots, Chinese angelica roots, bugleweed, lemongrass, dahurian angelica, rhizoma cimicifugae, wolfberry bark and egg white. The medicinal composition of the present invention is a medicine for external use, and has the advantages of short treatment cycle, good curative effect and little toxic and side effect on treating tuberculosis, particularly pulmonary tuberculosis.
Description
The present invention relates to a kind of tuberculosis composition and method of making the same, particularly a kind of pharmaceutical composition for the treatment of pulmonary tuberculosis and preparation method thereof.
Tuberculosis is a kind of serious harm people's healthy disease.Especially pulmonary tuberculosis owing to its strong infectiousness, has become a kind of principal disease of causing death in the world, and has been classified as one of pertinacious disease that has a strong impact on human body health by World Health Organization (WHO) and medical circle.Recently relevant report, the trend that pulmonary tuberculosis rate worldwide spreads and rises.The phthisical main medicine of existing treatment has two kinds of isoniazid and rifampicin, and is developing and developing the new drug and the compound preparation of other treatment pulmonary tuberculosis.In the phthisical medicine of existing treatment, all be to belong to injection and oral medicine, it inevitably produces in various degree side effect to other biorgans of human body.For example pulmonary tuberculosis patient can produce infringement to its liver and kidney when taking the medicine of treatment pulmonary tuberculosis.In addition, greatly casual property fibrotic cavitys tuberculosis is difficult to cure with existing medicine.In order to alleviate the toxic and side effects of medicine, medicine for external use is better.But up to the present, also do not find to have on the market external used medicine of treatment pulmonary tuberculosis to occur.
An object of the present invention is at the weak point of the medicine of existing treatment pulmonary tuberculosis and a kind of treatment tuberculosis is provided, especially the pharmaceutical composition of pulmonary tuberculosis.
Another object of the present invention provides a kind of method of pharmaceutical composition of preparation treatment tuberculosis, especially pulmonary tuberculosis.
The present inventor has absorbed the elite of Chinese medicine and has invented a kind of tuberculosis of can effectively treating through concentrating on studies of inventor, especially treats the pharmaceutical composition of pulmonary tuberculosis.With traditional treatment tuberculosis, especially treat the medicine of pulmonary tuberculosis different be, treatment tuberculosis of the present invention, the pharmaceutical composition of especially treating pulmonary tuberculosis is a medicine for external use, therefore can effectively treat tuberculosis, when especially treating pulmonary tuberculosis, pharmaceutical composition of the present invention reduces greatly to patient's toxic and side effects.
According to the present invention, the present invention relates to a kind of treatment tuberculosis, especially treat the pharmaceutical composition of pulmonary tuberculosis, wherein each this pharmaceutical composition of kilogram comprises:
Moschus 1-6 gram Radix Stemonae 50-80 gram
Herba Andrographis 100-120 gram Radix Asteris 20-40 gram
Radix Adenophorae Trachelioidis 30-60 gram Fructus Schisandrae Chinensis 100-130 gram
Radix Scutellariae 90-100 gram Leptoradix Ginseng 10-30 gram
Radix Bupleuri 30-50 gram Radix Sophorae Flavescentis 5-15 gram
Radix Angelicae Sinensis 40-70 gram wheel blade Herba Lycopi 90-100 gram
Herba Cymbopogonis 20-50 gram Radix Angelicae Dahuricae 30-50 gram
Rhizoma Cimicifugae 20-50 gram Cortex Lycii 30-60 gram
Surplus is an Ovum Gallus domesticus album.
According to the present invention, the invention still further relates to a kind of method for preparing aforesaid pharmaceutical composition, may further comprise the steps:
(1) Radix Bupleuri, wheel blade Herba Lycopi and Rhizoma Cimicifugae are soaked 3-with white vinegar by 1: 2 weight ratio respectively
5 hours, accompany drying 150-200 ℃ of baking then, grind into powder, and cross 100
The purpose sieve is got its siftage;
(2) will exist respectively except that other components Radix Bupleuri, wheel blade Herba Lycopi, Rhizoma Cimicifugae and the Ovum Gallus domesticus album
Drying is accompanied in 100-150 ℃ of baking, grind into powder, and 100 sieve is got its sieve down excessively
Thing;
(3) will be even by the powder mixes that step (1) and (2) obtain, be modulated into Ovum Gallus domesticus album
Paste obtains pharmaceutical composition of the present invention.
In recent years, tuberculosis especially pulmonary tuberculosis people healthy constituted increasing threat.The traditional treatment tuberculosis especially medicine of pulmonary tuberculosis all is oral medicine basically, and these medicines also caused damage to patient's other normal structures and cell inevitably in the treatment while lungy.Therefore, traditional treatment tuberculosis is the medicine and the method for pulmonary tuberculosis especially, and long for these disease treatment cycles of treatment, patient must stand the hardship of drug side effect.The present inventor and through the concentrating on studies of inventor, and has succeeded in developing a kind of tuberculosis of can effectively treating on the basis of the elite that absorbs Chinese medicine, especially treat the pharmaceutical composition of pulmonary tuberculosis.Pharmaceutical composition of the present invention adopts external drug for point, the method handy and safe, have no side effect, can be widely used in the various tuberculosis of treatment, especially various types of pulmonary tuberculosis, the diseases such as pulmonary abscess that cause as pulmonary tuberculosis, because of pulmonary tuberculosis, for example wettability pulmonary tuberculosis and cavitary pulmonary tuberculosis etc.Clinical trial certificate, pharmaceutical composition of the present invention to phthisical effective percentage more than 96%.
The present invention relates to a kind of treatment tuberculosis, especially treat the pharmaceutical composition of pulmonary tuberculosis, wherein each this pharmaceutical composition of kilogram comprises:
Moschus 1-6 gram Radix Stemonae 50-80 gram
Herba Andrographis 100-120 gram Radix Asteris 20-40 gram
Radix Adenophorae Trachelioidis 30-60 gram Fructus Schisandrae Chinensis 100-130 gram
Radix Scutellariae 90-100 gram Leptoradix Ginseng 10-30 gram
Radix Bupleuri 30-50 gram Radix Sophorae Flavescentis 5-15 gram
Radix Angelicae Sinensis 40-70 gram wheel blade Herba Lycopi 90-100 gram
Herba Cymbopogonis 20-50 gram Radix Angelicae Dahuricae 30-50 gram
Rhizoma Cimicifugae 20-50 gram Cortex Lycii 30-60 gram
Surplus is an Ovum Gallus domesticus album.
According to pharmaceutical composition of the present invention, wherein, each this pharmaceutical composition of kilogram preferably comprises:
Moschus 3-4 gram Radix Stemonae 60-70 gram
Herba Andrographis 100-110 gram Radix Asteris 20-30 gram
Radix Adenophorae Trachelioidis 40-50 gram Fructus Schisandrae Chinensis 120-130 gram
Radix Scutellariae 90-100 gram Leptoradix Ginseng 20-30 gram
Radix Bupleuri 30-40 gram Radix Sophorae Flavescentis 5-15 gram
Radix Angelicae Sinensis 50-60 gram wheel blade Herba Lycopi 90-100 gram
Herba Cymbopogonis 30-40 gram Radix Angelicae Dahuricae 35-45 gram
Rhizoma Cimicifugae 20-30 gram Cortex Lycii 40-50 gram
Surplus is an Ovum Gallus domesticus album.
Pharmaceutical composition of the present invention is a unguentum.During clinical use, also can earlier other active component elder generation mix homogeneously except that Ovum Gallus domesticus album be formed powder, mix with Ovum Gallus domesticus album again during actual medication and mix well the formation unguentum and be used for the patient.During use, with pharmaceutical composition of the present invention in six acupuncture point drug of topical application such as the external Shenmai of patient, gb 34, asthma point, Shenzhu, big vertebra and fei shus.
In the pharmaceutical composition of the present invention, all components are existing Chinese medicine medical material on the Chinese medicine market, can directly be commercially available from the market.
According to pharmaceutical composition of the present invention, wherein said Ovum Gallus domesticus album can be various poultry, for example the Ovum Gallus domesticus album of chicken, duck, goose egg, preferably egg white.
The invention still further relates to a kind of method for preparing aforesaid pharmaceutical composition, this method may further comprise the steps:
(1) Radix Bupleuri, wheel blade Herba Lycopi and Rhizoma Cimicifugae are soaked by 1: 2 weight ratio with tablet vinegar respectively
3-5 hour, accompany drying 150-200 ℃ of baking then, grind into powder, and mistake
100 purposes sieve is got its siftage;
(2) will exist respectively except that other components Radix Bupleuri, wheel blade Herba Lycopi, Rhizoma Cimicifugae and the Ovum Gallus domesticus album
Drying is accompanied in 100-150 ℃ of baking, grind into powder, and cross 100 purposes sieve and get its sieve down
Thing;
(3) will be even by the powder mixes that step (1) and (2) obtain, be modulated into Ovum Gallus domesticus album
Paste obtains pharmaceutical composition of the present invention.
With clinical experiment the present invention is described in more detail by the following examples.
Embodiment
Embodiment 1
40 gram Radix Bupleuri, 90 gram wheel blade Herba Lycopi and 20 gram liter fiber crops were soaked 3 hours with 400 grams, 700 grams and 400 gram tablet vinegar respectively, accompanied drying 180 ℃ of bakings respectively then, grind into powder sieves with 100 eye mesh screens, gets its siftage.
3 gram Moschus, the 60 gram Radixs Stemonae, 110 gram Herba Andrographis, 60 gram Radix Asteriss, 50 Ke Radix Adenophorae Trachelioidis, 130 gram Fructus Schisandrae Chinensis, 100 gram Radix Scutellariaes, 25 gram Leptoradix Ginsengs, 10 gram Radix Sophorae Flavescentiss, 55 gram Radix Angelicae Sinensis, 40 gram Herba Cymbopogoniss, the 45 gram Radixs Angelicae Dahuricae and 50 gram Cortex Lycii are accompanied drying 120 ℃ of bakings respectively, grind into powder, sieve with 100 eye mesh screens, get its siftage.
The above-mentioned powder mixes that obtains is even, add 120 gram Ovum Gallus domesticus album, be in harmonious proportion evenly, obtain pharmaceutical composition of the present invention.
Embodiment 2-6
Adopt the method identical with embodiment 1, the consumption that is each component is as shown in table 1 below.The consumption of each component all is unit with the gram.
Table 1
| Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 | |
| Radix Bupleuri | 30 | 30 | 50 | 35 | 30 |
| The wheel blade Herba Lycopi | 90 | 90 | 100 | 90 | 95 |
| Rhizoma Cimicifugae | 20 | 40 | 25 | 35 | 50 |
| Moschus | 1 | 6 | 2 | 4 | 5 |
| The Radix Stemonae | 50 | 50 | 60 | 70 | 80 |
| Herba Andrographis | 100 | 100 | 120 | 100 | 110 |
| Radix Asteris | 20 | 40 | 25 | 35 | 40 |
| Radix Adenophorae Trachelioidis | 30 | 60 | 35 | 50 | 45 |
| Fructus Schisandrae Chinensis | 100 | 100 | 110 | 130 | 100 |
| Radix Scutellariae | 90 | 100 | 100 | 90 | 90 |
| The Leptoradix Ginseng | 10 | 30 | 15 | 20 | 25 |
| Radix Sophorae Flavescentis | 5 | 1 5 | 6 | 8 | 12 |
| Radix Angelicae Sinensis | 40 | 60 | 45 | 70 | 50 |
| Herba Cymbopogonis | 20 | 40 | 25 | 50 | 20 |
| The Radix Angelicae Dahuricae | 30 | 50 | 35 | 40 | 40 |
| Cortex Lycii | 30 | 60 | 35 | 40 | 45 |
| Ovum Gallus domesticus album | To 1000 grams | To 1000 grams | To 1000 grams | To 1000 grams | To 1000 grams |
Clinical experiment
Adopting pharmaceutical composition of the present invention to carry out treatment tuberculosis, mainly is the clinical experiment of treatment pulmonary tuberculosis.Experimental result is as follows.Experimental example 1 pharmaceutical composition of the present invention is to the clinical therapeutic efficacy of old pulmonary tuberculosis
The pharmaceutical composition that adopts embodiment 1 to obtain carries out clinical treatment to 38 routine old pulmonary tuberculosis patients.The pharmaceutical composition that embodiment 1 is obtained applies at six acupuncture points such as the external Shenmai of patient, gb 34, asthma point, Shenzhu, big vertebra and fei shus, and the drug of topical application amount at each acupuncture point is 6 grams, changes every day 1 time, is one with 6 days and treats the course of treatment.Observe the statistics therapeutic effect after 4 courses of treatment.The result is as shown in table 2 below.
The pharmaceutical composition that adopts embodiment 2 to obtain carries out clinical treatment to 33 routine old pulmonary tuberculosis patients.The pharmaceutical composition that embodiment 2 is obtained applies at six acupuncture points such as the external Shenmai of patient, gb 34, asthma point, Shenzhu, big vertebra and fei shus, and the drug of topical application amount at each acupuncture point is 6 grams, changes every day 1 time, is one with 6 days and treats the course of treatment.Observe the statistics therapeutic effect after 4 courses of treatment.The result is as shown in table 2 below.Table 2
Experimental example 2 pharmaceutical compositions of the present invention are to the clinical therapeutic efficacy of cavitary pulmonary tuberculosis disease
| Patient's number | Invalid | Effectively | Produce effects | Cure | Compositions |
| 38 | 0 | 6 | 11 | 21 | Embodiment 1 |
| 33 | 0 | 9 | 13 | 11 | Embodiment 2 |
The pharmaceutical composition that adopts embodiment 3 to obtain carries out clinical treatment to the sick patient of 21 routine cavitary pulmonary tuberculosises.The pharmaceutical composition that embodiment 3 is obtained applies at six acupuncture points such as the external Shenmai of patient, gb 34, asthma point, Shenzhu, big vertebra and fei shus, and the drug of topical application amount at each acupuncture point is 6 grams, changes every day 1 time, is one with 6 days and treats the course of treatment.Observe the statistics therapeutic effect after 4 courses of treatment.The result is as shown in table 3 below.
The pharmaceutical composition that adopts embodiment 4 to obtain carries out clinical treatment to the sick patient of 19 routine cavitary pulmonary tuberculosises.The pharmaceutical composition that embodiment 4 is obtained applies at six acupuncture points such as the external Shenmai of patient, gb 34, asthma point, Shenzhu, big vertebra and fei shus, and the drug of topical application amount at each acupuncture point is 6 grams, changes every day 1 time, is one with 6 days and treats the course of treatment.Observe the statistics therapeutic effect after 4 courses of treatment.The result is as shown in table 3 below.Table 3
Experimental example 3 pharmaceutical compositions of the present invention are to the clinical therapeutic efficacy of primary pulmonary tuberculosis disease
| Patient's number | Invalid | Effectively | Produce effects | Cure | Compositions |
| 21 | 0 | 10 | 6 | 5 | Embodiment 3 |
| 19 | 0 | 5 | 3 | 11 | Embodiment 4 |
The pharmaceutical composition that adopts embodiment 5 to obtain carries out clinical treatment to the sick patient of 13 routine primary pulmonary tuberculosis.The pharmaceutical composition that embodiment 5 is obtained applies at six acupuncture points such as the external Shenmai of patient, gb 34, asthma point, Shenzhu, big vertebra and fei shus, and the drug of topical application amount at each acupuncture point is 6 grams, changes every day 1 time, is one with 6 days and treats the course of treatment.Observe the statistics therapeutic effect after 4 courses of treatment.The result is as shown in table 4 below.
The pharmaceutical composition that adopts embodiment 6 to obtain carries out clinical treatment to the sick patient of 18 routine primary pulmonary tuberculosis.The pharmaceutical composition that embodiment 6 is obtained applies at six acupuncture points such as the external Shenmai of patient, gb 34, asthma point, Shenzhu, big vertebra and fei shus, and the drug of topical application amount at each acupuncture point is 6 grams, changes every day 1 time, is one with 6 days and treats the course of treatment.Observe the statistics therapeutic effect after 4 courses of treatment.The result is as shown in table 4 below.Table 4
| Patient's number | Invalid | Effectively | Produce effects | Cure | Compositions |
| 13 | 0 | 3 | 3 | 7 | Embodiment 5 |
| 18 | 0 | 5 | 2 | 11 | Embodiment 6 |
Model caseModel case 1
The patient horse * *, the woman 47 years old, suffers from casual property fibro cavernous pulmonary tuberculosis, expectorant bacterium (+).Before adopting medicine composite for curing of the present invention, once used isoniazid, streptomycin, isoniazid, rifampicin, base salicyate therapy 6 years, with crossing broken soup ball of Chinese medicine ferrum and Pseudobulbus Bletillae (Rhizoma Bletillae) treatment, also used the artificial pneumoperitoneum treatment, successively be in hospital 4 times, each 3-4 month, used various Chinese and Western hemorrhage, as hypophysis cerebri, vitamin K, carbazochrome salicylate, reptilase etc., be clearly better but stop blooding all not have, hemoptysis or apoplexy due to phlegm often show effect repeatedly for blood, and it is fixed to examine through the tuberculosis expert, this sick medical treatment is invalid, answer the capable lobectomy of lungs of surgical operation, because of family members do not disagree with, sb.'s illness took a turn for the worse in the back, the expert diagnosis treatment is with thoroughly hopeless, in mid-June, 2000, during tuberculosis hospital's ambulance is sent back home, become comatose state.The diagnosis and treatment of being invited, X-ray photograph shows that its left lung has three cavities, big 4.5X3, minimum 3X2, right lung have rotted 2/3, overflow the property fibro cavernous pulmonary tuberculosis, exudative peritonitis, getting rid of peritoneal effusion every day is 3000 milliliters, coma in moderate depth is critically ill.Adopt pharmaceutical composition of the present invention to treat, in patient's Shenmai, gb 34, asthma point, Shenzhu, big Chui, six acupuncture point drug of topical application of fei shu, consumption is each acupuncture point 6 gram, and patient is clear-headed after 30 hours, spitting of blood stops, the patient had hunger sensation in 50 hours, with about gruel 200 grams, changed dressings in 72 hours, the patient can sit up, changed dressings 1 time in per three days later on, changed dressings 6 times in 18 days, the patient can walk.X-ray photograph shows that its left pulmonary cavity disappears, and right lung has regenerated 1/3, forms the garden tangent plane, increased bronchovascular shadows, and tuberculosis is cured substantially, 2 kilometers hill paths back and forth, the patient does not have the symptom of panting, and makes expectorant and examines, and is negative.Adhere to that with about 60 days existing patient can do housework, can do some suitable physical works, nearly Radix Stephaniae Tetrandrae is thoroughly cured.Model case 2
Liu * *, the woman 29 years old, suffered from casual property fibro cavernous pulmonary tuberculosis 8 years.Before adopting medicine composite for curing of the present invention, once use Chinese medicine and western medicine such as isoniazid, streptomycin, aminosalicylic acid, isoniazid, all do not have positive effect.X-ray photograph shows eight cavities of two lungs size, and the wall film in cavity has thicker fibrous tissue to surround, the lung tissue around the cavity, the progressive focus of sending out is arranged, on the empty wall, bigger aneurysm rupture is arranged, so produce a large amount of spitting of bloods, patient's readme, cough, expectoration, sputum become to be purulence, aversion to cold appears in band blood sometimes, and body heat is up to the 39-40 degree, chest pain is breathed hard, and night sweat is weak, agitation can not be taken food before the treatment, keeps by 5% glucose, Ostwald-Folin star.Adopt pharmaceutical composition of the present invention to treat, to patient's Shenmai, gb 34, asthma point, Shenzhu, big vertebra, six acupuncture point drug of topical application of fei shu, each drug for point 6 gram, changed dressings in 3 days, the patient in medication 24 as a child feels that cough alleviates, and spitting of blood stops, chest pain alleviates, hunger sensation is arranged, and the patient can take action when changing dressings in 3 days, life can be taken care of oneself, and continuous use was changed dressings 8 times in 24 days.X-ray photograph after the treatment shows that its two pulmonary cavity closes, clinical tuberculosis transference cure, and no tuberculosis signs of toxicity, the expectorant bacterium checks and is negative that the focus inflammation disappears to bottom line.Diagnosis, clinical recovery.Model case 3
The king * *, man, 65 years old, sick more than 20 year of hectic.Before adopting medicine composite for curing of the present invention, the patient feels that the whole body is unable, nauseating, irritated, coughs, is with sometimes blood, night sweat chest pain.Speckle nodositas on its two lobe of the lung of X-ray photograph, density is higher, clear-cut margin, the cheese kitchen range that fiber surrounds has annular boundary, and does not wait the cavity of lucent area (3 * 4.2), and many places are with emphysema and pulmonary abscess.Adopt pharmaceutical composition of the present invention to treat, to patient's Shenmai, gb 34, asthma point, Shenzhu, big vertebra, fei shu, carry out the drug of topical application, dose is each acupuncture point 6 gram, changed once in per 3 days, carried out clinical treatment 30 days, and changed dressings 10 times, the patient feels that the whole body is strong, cough alleviates, expectorant reduces, and spitting of blood stops, competent general muscular labor.X-ray photograph after the treatment shows its foci disappearance, and lung marking is normal, and the cavity is closed, clinical diagnosis, and pulmonary tuberculosis is cured.The expectorant bacterium is checked and is negative.Model case 4
Xing Liu Shi, the woman, 69 years old, the self-induction chest pain was breathed hard, and suffers from pulmonary tuberculosis, not fertility, the 30-40 that cures the disease, night, night sweat was stuffy, general weakness.Every year is all in treatment, but therapeutic effect is not remarkable.X-ray photograph shows its thickening property of peritoneum variation, peritoneal adhesion tuberculosis of intestine, ascites, intestinal obstruction, enteric cavity lumps outward, phenomenons such as small intestinal knot fistula, ascites checks that ascites is the olive drab(O transudate, after leaving standstill, solidify in bulk voluntarily, the sticking white qualitative experiment of ascites is positive, and ascites concentrates direct smear, find acid-fast bacilli, ascites is cultivated, and tulase is positive, is diagnosed as tuberculous peritonitis.Adopt pharmaceutical composition of the present invention, to patient's Shenmai, gb 34, asthma point, Shenzhu, big vertebra, the fei shu drug of topical application, every acupuncture point is 6 grams, changes medicine one time in 3 days, treats 42 days 6 days one courses of treatment, and chest pain disappears entirely, and it is normal to breathe.X-ray photograph after the treatment shows that its peritoneum is normal, and peritoneal adhesion disappears, tuberculosis of intestine, and ascites, intestinal obstruction, the enteric cavity lower abdomen knot fistula that lumps outward disappears.Diagnosis: clinical tuberculous peritonitis disappears, clinical cure.
Above experimental result shows that pharmaceutical composition of the present invention can effectively be treated various tuberculosis, and especially various pulmonary tuberculosis are evident in efficacy, and treatment cycle is short.Simultaneously, because pharmaceutical composition of the present invention is by treated in vitro, so its toxicity and side effect reduce greatly.
Claims (7)
1, a kind of tuberculosis composition for the treatment of is characterized in that each this pharmaceutical composition of kilogram is made up of following component: Moschus 1-6 gram tuber of stemona 50-80 gram Herba Andrographitis 100-120 gram aster 20-40 Ke Ji Ni 30-50 gram fruit of Chinese magnoliavine 100-130 gram root of large-flowered skullcap 90-100 gram ginseng fibrous root 10-30 gram radix bupleuri 30-50 gram kuh-seng 5-15 gram Radix Angelicae Sinensis 40-70 gram wheel blade Herba Lycopi 90-100 gram cymbopogon distans 20-50 gram root of Dahurain angelica 30-50 gram liter fiber crops 20-50 gram root bark of Chinese wolf-berry 30-60 gram surplus is egg white.
2, pharmaceutical composition as claimed in claim 1 is characterized in that each this pharmaceutical composition of kilogram is made up of following component: Moschus 3-4 gram tuber of stemona 60-70 gram Herba Andrographitis 100-110 gram aster 20-30 Ke Ji Ni 40-50 gram fruit of Chinese magnoliavine 120-130 gram root of large-flowered skullcap 90-100 gram ginseng fibrous root 20-30 gram radix bupleuri 30-40 gram kuh-seng 5-10 gram Radix Angelicae Sinensis 50-60 gram wheel blade Herba Lycopi 90-100 gram cymbopogon distans 30-40 gram root of Dahurain angelica 35-45 gram liter fiber crops 20-30 gram root bark of Chinese wolf-berry 40-50 gram surplus is egg white.
3, pharmaceutical composition as claimed in claim 1 or 2 is characterized in that described Ovum Gallus domesticus album is Ovum Gallus domesticus album, Ovum Anas domestica album or goose albumen.
4, pharmaceutical composition as claimed in claim 3 is characterized in that described Ovum Gallus domesticus album is Ovum Gallus domesticus album.
5, a kind of method for preparing pharmaceutical composition as claimed in claim 1:
(1) Radix Bupleuri, wheel blade Herba Lycopi and Rhizoma Cimicifugae are soaked by 1: 2 weight ratio with white vinegar respectively
3-5 hour, accompany drying 150-200 ℃ of baking then, grind into powder, and mistake
100 purposes sieve is got its siftage;
(2) will exist respectively except that other components Radix Bupleuri, wheel blade Herba Lycopi, Rhizoma Cimicifugae and the Ovum Gallus domesticus album
Drying is accompanied in 100-150 ℃ of baking, grind into powder, and cross 100 purposes sieve and get its sieve
Following thing;
(3) will be even by the powder mixes that step (1) and (2) obtain, be modulated into Ovum Gallus domesticus album
Paste obtains pharmaceutical composition of the present invention.
6, method as claimed in claim 5 is characterized in that described Ovum Gallus domesticus album is Ovum Gallus domesticus album, Ovum Anas domestica album or goose albumen.
7, method as claimed in claim 6 is characterized in that described Ovum Gallus domesticus album is Ovum Gallus domesticus album.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011156023A CN1136894C (en) | 2001-04-26 | 2001-04-26 | Medicinal composition for treating tuberculosis and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB011156023A CN1136894C (en) | 2001-04-26 | 2001-04-26 | Medicinal composition for treating tuberculosis and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1325720A CN1325720A (en) | 2001-12-12 |
| CN1136894C true CN1136894C (en) | 2004-02-04 |
Family
ID=4662091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011156023A Expired - Fee Related CN1136894C (en) | 2001-04-26 | 2001-04-26 | Medicinal composition for treating tuberculosis and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1136894C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106138185A (en) * | 2016-08-24 | 2016-11-23 | 张仕英 | Strengthen the external medicine composition of lung vigor, its preparation method and using method |
| CN110407918B (en) * | 2019-07-22 | 2021-06-18 | 上海交通大学医学院附属瑞金医院 | Temperature-sensitive targeted fluorescent probe and preparation method and application thereof |
-
2001
- 2001-04-26 CN CNB011156023A patent/CN1136894C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1325720A (en) | 2001-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1061854C (en) | Medicinal preparation for treatment and prevention of gynopathy | |
| CN1742939A (en) | Medicine for treating pulmonary fibrosis and preparing method | |
| CN102247581B (en) | Medicament for treating myoma of uterus | |
| CN101049368A (en) | Oral and external remedy for curing psoriasis | |
| CN1872180A (en) | Medication of membranous milk vetch for activating blood and the channels, and preparation method | |
| CN1210047C (en) | Medicine for treating cold and preparation method thereof | |
| CN1112836A (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN1390585A (en) | Chinese medicine for detoxication purpose and its preparing process | |
| CN101317965B (en) | Traditional Chinese medicinal preparation for treating cancer | |
| CN1272066C (en) | Medicinal composition for relieving itching | |
| CN1136894C (en) | Medicinal composition for treating tuberculosis and its preparing process | |
| CN1931277A (en) | Osteoarthrosis treating Chinese medicine composition and its prepn process | |
| CN1280841A (en) | Medicine for treating hepatitis B and rheumatoid diseases | |
| CN1108810C (en) | Medicine for treating psoriasis and preparing process thereof | |
| CN1895593A (en) | Medicine for treating acne and its preparation | |
| CN1111046C (en) | Chinese medicine preparation for curing postpartum disease of woman | |
| CN1385187A (en) | Medicinal composition, its preparation process and use in treating psoriasis | |
| CN101045143A (en) | Medicine for quickly treating high fever due to tuberculosis and pneumonitis and its preparing method | |
| CN1973876A (en) | Chinese medicine for treating kidney deficiency and its prpen | |
| CN1246019C (en) | Chinese medicine preparation for curing angitis | |
| CN1876061A (en) | A medicine for treating hepatitis | |
| CN1253195C (en) | Anti-age capsule of traditional Chinese medicine and preparation method | |
| CN1068523C (en) | Medicine for treating cancer and its preparing technology | |
| CN1739749A (en) | Leukemia treating Chinese medicine composition and its prepn | |
| CN1739710A (en) | Medicine for treating rheumarthritis and traumatic injury pain and its prpen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040204 |